Guillain-Barre syndrome in southern Chinese children: 32 year experience in Hong Kong

被引:12
作者
Ma, Yee-man [2 ]
Liu, Tim K. T. [2 ]
Wong, Virginia [1 ]
机构
[1] Univ Hong Kong, Dept Paediat & Adolescent Med, Div Child Neurol Dev Paediat Neurohabilitat, Hong Kong, Hong Kong, Peoples R China
[2] Univ Hong Kong, Dept Paediat & Adolescent Med, Pamela Youde Nethersole Eastern Hosp, Hong Kong, Hong Kong, Peoples R China
关键词
acute inflammatory demyelinating polyradiculoneuropathy; children; Chinese; Guillain-Barre syndrome; immunoglobulin; INTRAVENOUS IMMUNOGLOBULIN; CLINICAL-COURSE; CHILDHOOD; THERAPY; EPIDEMIOLOGY; INFECTION; PROGNOSIS; TRIAL;
D O I
10.1111/j.1442-200X.2009.02951.x
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background: The purpose of the present study was to investigate the clinical pattern of Guillain-Barre syndrome (GBS) in southern Chinese children in Hong Kong and to compare the clinical outcome of early versus delayed intervention with i.v. immunoglobulin (IVIg). Methods: A retrospective review of medical records of GBS patients admitted to two hospitals on Hong Kong Island during a 32 year period (1976-2008) was performed. Clinical outcome was compared for early versus late IVIg treatment, using a 7 day cut-off. This analysis was then repeated using a 10 day cut-off. Results: Of 34 children, 22 (65%) had preceding illness but no infective etiology could be identified. Nerve conduction was measured in 17 (50%): nine had demyelinating neuropathy, three had axonal neuropathy with demyelinating features, two had pure axonal neuropathy, and one was normal. In two patients with Miller-Fisher syndrome (MFS) the studies showed additional abnormal sensory conduction. Twenty-one received conservative treatment only. Ten (29%) received IVIg, two (6%) received plasmapheresis and three (9%) received corticosteroid. Thirty-one (91%) had complete recovery, two (6%) had long-term morbidity and one died of respiratory failure. Comparison of the early and late IVIg treatment groups for each cut-off showed no statistically significant difference in clinical outcome. A longer period of hospital stay and longer time to improve one disability grade, however, were noted for the late treatment group for both cut-offs. Conclusions: The clinical profile of GBS in southern Chinese children in Hong Kong is provided. There was no statistically significant difference between early versus delayed treatment with IVIg.
引用
收藏
页码:13 / 19
页数:7
相关论文
共 50 条
  • [21] Evaluating the Status of Antiganglioside Antibodies in Children with Guillain-Barre Syndrome
    Hashemilar, Mazyar
    Barzegar, Mohammad
    Nikanfar, Masoud
    Bonyadi, Mohammad Reza
    Goldust, Mohamad
    Ramouz, Ali
    Ebrahimi, Faeghe
    NEUROIMMUNOMODULATION, 2014, 21 (01) : 64 - 68
  • [22] EMG and duration of ventilatory support in children with Guillain-Barre syndrome
    Ortiz-Corredor, Fernando
    Diaz-Ruiz, Jorge
    Izquierdo-Bello, Alvaro
    CHILDS NERVOUS SYSTEM, 2006, 22 (10) : 1328 - 1331
  • [23] Hyponatraemia in Guillain-Barre syndrome revisited
    Hiew, F. L.
    Winer, J. B.
    Rajabally, Y. A.
    ACTA NEUROLOGICA SCANDINAVICA, 2016, 133 (04): : 295 - 301
  • [24] Therapeutic issues in Guillain-Barre syndrome
    Magy, Laurent
    Frachet, Simon
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2023, 23 (06) : 549 - 557
  • [25] Guillain-Barre syndrome: A comprehensive review
    Bellanti, Roberto
    Rinaldi, Simon
    EUROPEAN JOURNAL OF NEUROLOGY, 2024, 31 (08)
  • [26] Emerging drugs for Guillain-Barre syndrome
    Walgaard, Christa
    Jacobs, Bart C.
    van Doorn, Pieter A.
    EXPERT OPINION ON EMERGING DRUGS, 2011, 16 (01) : 105 - 120
  • [27] Guillain-Barre syndrome and cytomegalovirus infection during pregnancy
    Lupo, Julien
    Germi, Raphaele
    Jean, Dominique
    Baccard-Longere, Monique
    Casez, Olivier
    Besson, Gerard
    Rouge, Alain
    Boutonnat, Jean
    Schwebel, Carole
    Hoffmann, Pascale
    Morand, Patrice
    JOURNAL OF CLINICAL VIROLOGY, 2016, 79 : 74 - 76
  • [28] Immune globulin therapy in children with Guillain-Barre syndrome
    Goodhew, PM
    Johnston, HM
    MUSCLE & NERVE, 1996, 19 (11) : 1490 - 1492
  • [29] Immunoglobulin and Monoclonal Antibody Therapies in Guillain-Barre Syndrome
    Rajabally, Yusuf A.
    NEUROTHERAPEUTICS, 2022, 19 (03) : 885 - 896
  • [30] Use of immunoglobulin in severe childhood Guillain-Barre syndrome
    Ortiz-Corredor, F.
    Pena-Preciado, M.
    ACTA NEUROLOGICA SCANDINAVICA, 2007, 115 (04): : 289 - 293